CNS Efficacy, Regimen Selection, and Quality-of-Life Considerations

This segment drills into CNS efficacy and how it shapes regimen selection. Prospective serial brain MRI data from Mariposa are contrasted with less granular CNS follow-up from other trials, giving clinicians greater confidence when choosing combination therapy for patients with brain metastases. The conversation then compares chemo plus osimertinib versus non‑chemotherapy bispecific antibody plus TKI regimens. The chemotherapy backbone is described as familiar and finite, with expected hematologic and fatigue toxicity but predictable three-weekly clinic visits and potential de‑escalation to TKI alone. The non‑chemotherapy regimen avoids cytotoxic chemotherapy yet carries a prominent early dermatologic toxicity burden and, historically, infusion-related reactions, now mitigated by subcutaneous delivery. Patient-reported outcomes and real-world quality-of-life considerations are emphasized as crucial, since trial-defined tolerability may not reflect individual experiences. The episode underscores that treatment choice often hinges on balancing survival and CNS benefits against visible rash, clinic time, and patient lifestyle priorities.